Leaders Eric Dobmeier and Joanne Waldstreicher to its Board of Directors GPCR Therapeutics launches multiple myeloma trial Salipro Biotech is attending the 3rd Advanced Therapy Showcase in Tokyo, Japan, organized

mind-bending’ research collaborations GPCR Therapeutics Announces Launch of US Phase 2 Trial of GPC-100 in Multiple Myeloma Call for GPCR Papers GPCRs: Signal Transduction.

, and more GPR84 in physiology - many functions in many tissues Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast Structural and Molecular Insights into GPCR Function Structural

Immunology Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma Published date August 22, 2024 Abstract "Multiple myeloma (MM) is a complex hematological malignancy Authors Jihong Jeong, Junhyeon Park, Geun Young Mo, Jinwoo Shin, Yunje Cho Tags GPRC5D , Multiple myeloma

investigational autologous BCMA CAR T-cell products at the recommended phase 2 dose) for relapsed/refractory multiple myeloma between November 2016 and May 2022.

GPCR News < GPCRs in Oncology and Immunology The orphan G protein-coupled receptor 141 expressed in myeloid High GPR141 messenger RNA levels were expressed in myeloid-lineage cells, including neutrophils (CD11b Gpr141 -/- mice, which we independently generated, displayed almost no abnormalities in myeloid cell exacerbated disease conditions of experimental autoimmune encephalomyelitis, an autoimmune disease model for multiple 141 , autoimmune disease , dendritic cells , experimental autoimmune encephalomyelitis , monocytes , myeloid